Skip to main content
. 2022 Jan 21;12:804250. doi: 10.3389/fphar.2021.804250

FIGURE 2.

FIGURE 2

(A) Results from randomized controlled trials (RCTs): the mortality outcome of tocilizumab for COVID-19 (at the edge of sepsis).